scholarly journals IS CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME ASSOCIATED WITH CHRONIC RHINOSINUSITIS?: A STUDY BASED ON “NATIONAL INSTITUTE OF HEALTH- CHRONIC PROSTATITIS SYMPTOM INDEX” AND “SINONASAL OUTCOME TEST-22” QUESTIONNAIRES

2021 ◽  
Author(s):  
Ahmet Serdar Teoman ◽  
Ilke Onur Kazaz ◽  
Rasin Ozyavuz ◽  
Osman Bahadir ◽  
Bunyamin Kutlu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Symptom Index ◽  
Sinonasal Outcome Test ◽  
Snot 22

Objectives/Aims: Prostatitis is a common entity that is seen in younger than 50 years old men in urology clinics. Subcategory of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) accounts for more than 90% of cases of prostatitis and heterogeneous symptoms cause negative impact on quality of life. Chronic rhinosinusitis (CRS) is a common inflammatory disease of the upper airways and results in a constellation of symptoms that have a significant negative effect on a patient’s quality of life, either. However, both of these entities may share an inflammatory background because of systemic inflammatory responses and endocrine effects of cytokines. In this study, we aimed to find if any symptomatic correlation between CP/CPPS and CRS that can be measurable with National Institute of Health- Chronic Prostatitis Symptom Index (NIH-CPSI) and Sinonasal Outcome Test-22 (SNOT-22) validated symptom scores. Methods: Patients from urology (n:113) and ear-nose-throat (ENT) clinics (n:104) are included in this study. They were questionned with NIH-CPSI and SNOT-22. Also, they were evaluated if there was a correlation between these scores and some parameters (e.g. age, marital status, smoking, masturbation frequency, concomitant inflammatory diseases). Results: As our main result we found out a low-moderate correlation between NIH-CPSI and SNOT-22 scores (r:0.370 for urology, r: 0.466 for ENT patients). Conclusions: In this study we found that, CP/CPPS and CRS have a low correlated relationship symptomatically. We suggest that with further studies and additional data, CP/CPPS and CRS symptom relation might have been connected to a possible main root.

87: Biopsychosocial Factors in Quality of Life in men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

2007 ◽  
Vol 177 (4S) ◽  
pp. 31-31
Author(s):  
J. Curtis Nickel ◽  
Dean Tripp ◽  
Shannon Chuai ◽  
Mark S. Litwin ◽  
Mary McNaughton-Collins
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome

scholarly journals Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome

2018 ◽  
Vol 10 (12) ◽  
pp. 377-381 ◽  
Author(s):  
Andrea Benelli ◽  
Simone Mariani ◽  
Virginia Varca ◽  
Andrea Gregori ◽  
Franco Barrese ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Once Daily ◽  
International Prostatic Symptom Score

Background: Chronic prostatitis/chronic pelvic pain syndrome (IIIB CP/CPPS) is a condition of unclear aetiology. Many approaches have been used without satisfactory results. The aim of this study is to evaluate the efficacy of once-daily 5 mg tadalafil in pain control and improving quality of life in patients affected by CP/CPPS. Methods: Twenty patients affected by chronic prostatitis according EAU (European Association of Urology) guidelines were evaluated for once-daily 5 mg tadalafil; 14 patients were eligible for the study. The validated Italian version of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the International Prostatic Symptom Score (IPSS) questionnaires were submitted to all the patients. Every patient underwent uroflowmetry and ultrasound prostatic volume at the beginning and at the end of the study. Results: All 14 patients eligible for the study reported an improvement of symptoms during therapy: statistically significant differences were reported in terms of NIH-CPSI ( p < 0.000002) and IPSS ( p < 0.0001) during follow-up evaluations. No statistically significant improvement of uroflowmetry parameters was reported during the treatment. Conclusions: In our study the daily use of 5 mg tadalafil improves symptoms and quality of life in patients affected by CP/CPPS after 4 weeks of therapy. A larger population of patients is needed to confirm the efficacy of this therapy in CP/CPPS.

scholarly journals Uretharal syndrome in men-chronic pelvic pain syndrome

2009 ◽  
Vol 56 (1) ◽  
pp. 81-89 ◽  
Author(s):  
B.R. Cvetkovic ◽  
Z.P. Cvetkovic ◽  
D. Milenkovic ◽  
A. Adamovic
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Significant Influence ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Symptom Index ◽  
Pain Symptoms

Introduction: Chronic pelvic pain syndrome (CPPS) is defined as pelvis minor pain of nonmalignant nature repeating in different time intervals. Urethral syndrome (US) represents a most poorly defined entity within CPPS. Objective: The estimation of US influence on quality of-life as well as the determination of the way of treatment and therapy optimal length. Material and methods: A prospective one-year study included 166 men with CPPS, median age of 54 years; they were monitored clinically. During the patient monitoring the NIH-CPSI questionnaire (National Institute of Health- Chronic Prostatis Symptom Index) was used. US was diagnosed in 79 patients (47%), and according to the most intensive pain localization they were divided into three groups. All the patients were treated with alpha adrenergic blockers and non-steroidal anti-inflammatory drugs, and the treatment of the patients with positive urethral smear also included antibiotherapy. The values of total NIHCPSI, as well as of its individual components were analyzed after three and six months of treatment. Results and discussion: The therapy application had a significant influence on the decrease of total NIH-CPSI - 23.3% (p<0,01), pain symptoms (p<0.0) and urinary difficulties (p<0.01), and the point values of quality-of-life score were diminished by 0.7 to 1.9 points depending on the group of those monitored (p<0.01). Conclusion: Our study indicated a significant influence of CPPS on quality-of-life and a necessity of a serious approach to patients and their treatment.

scholarly journals The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids

2019 ◽  
Vol 90 (4) ◽  
pp. 260-264 ◽  
Author(s):  
Angela Maurizi ◽  
Francesco De Luca ◽  
Antonino Zanghi ◽  
Emy Manzi ◽  
Costantino Leonardo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Waiting Time ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Symptom Index ◽  
Average Waiting Time

Introduction: Chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) represents a challenge for the urologist, since the therapeutic efficacy does not always result in a satisfactory quality of life for the patients. Often the side effects of the medications used (antiinflammatories, antibiotics, alpha blockers) far outweighs the benefits gained with their admission. The choice of nutraceutical medications is preferred for their effectiveness, that has been accepted and proven by the scientific community, and for the low incidence of side effects. The objective of this study to compare the therapeutic efficacy of the flower pollen extracts (Deprox®) versus Bioflavonoids in terms of reduction of symptoms, and in the average waiting time of the variation of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and to evaluate the quality of life improvement of the patients affected by CP/CPPS. Methods: Among the 68 patients presented with prostatic symptoms to the Hospital “Umberto I” in Rome, Italy between March 2016 and June 2016, 54 patients met the clinical diagnosis of CP/CPPS (class IIIa or IIIb according to the NIH classification). The patients were assigned to either treatment with Deprox® or quercetin based on a randomization scheme previously determined.The NIH- CPSI, IPSS, QoL questionnaires were administered. Every patient underwent bacterial cultures and trans-rectal ultrasound. Results: There was a statistically significant improvement of the NIH-CPSI score and QoL in the Deprox® group (p = < 0.0001 and p = 0.003 respectively). The average waiting time of the variation of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) was statistically significant (p = 0.0019). In the absence of efficacy of the “conventional” medications, which also carries significant side effects, the dietary supplements may represent a valid alternative. Conclusions: DEPROX® has demonstrated a significant improvement of the symptoms and quality of life of patients diagnosed with by CP/CPPS. Furthermore, there was a statistical difference in the average waiting time of the variation of the NIH-CPSI) score without side effects as compared to the bioflavonoids complex with quercetin.

scholarly journals The use of Cinnamon (Cinnamomum Bark) for Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Randomized Controlled Trial

2020 ◽  
Vol 8 (B) ◽  
pp. 439-445
Author(s):  
Harth Mohamed Kamber ◽  
Tawfiq Jasim Mohammed Al-Marzooq ◽  
Malath Anwar Hussein ◽  
Qays Ahmed Hassan ◽  
Ahmed Abid Marzouq
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Urinary Symptoms ◽  
Secondary Outcome ◽  
Pelvic Pain Syndrome

BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is common, yet no curative treatment identified. Cinnamon is a herbal substance, which has many applications in medicine. AIM: The aim of the study was to study the effect of cinnamon on patients with chronic pelvic pain syndrome. METHODS: Sixty patients with documented CP/CPPS randomized into two groups during 2018 and 2019 in Baghdad. The first group received 60 capsules each contained 1 g of cinnamon. The other group received 60 capsules each contained 1 g of sugar powder (placebo). All the patients instructed to take one capsule twice daily for 1 month. National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) was reported for both groups at baseline and after 1 month of treatment. The primary outcome was a patient perceivable improvement defined as a reduction of the NIH-CPSI by 6 or more points after 1 month, whereas improvement of sub-scores of NIH-CPSI (pain, urinary symptoms, and quality of life) considered as a secondary outcome, and adverse reactions reported. RESULTS: Thirteen patients (43.3%) of the cinnamon group have 6 or more points of reduction in the total NIH-CPSI compared to four patients (13.3%) of the control groups (p = 0.01). The improvement in total NIH-CPSI score was mainly due to improvement in pain sub-score, whereas in urinary symptoms, there was marginal change with no significant change in the quality of life score. The only reported side effect was gastric upset in one patient. CONCLUSION: The study concluded that cinnamon improves NIH-CPSI in patients with CP/CPPS. REGISTRATION: The study was registered on ClinicalTrials.gov with the ID: NCT03946163.

scholarly journals Extracorporeal Shockwave Therapy (ESWT) Alleviates Pain, Enhances Erectile Function and Improves Quality of Life in Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

2021 ◽  
Vol 10 (16) ◽  
pp. 3602
Author(s):  
Wen-Ling Wu ◽  
Oluwaseun Adebayo Bamodu ◽  
Yuan-Hung Wang ◽  
Su-Wei Hu ◽  
Kai-Yi Tzou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Erectile Function ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
The Mean

Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), affecting over 90% of patients with symptomatic prostatitis, remains a therapeutic challenge and adversely affects patients’ quality of life (QoL). This study probed for likely beneficial effects of ESWT, evaluating its extent and durability. Patients and methods: Standardized indices, namely the pain, urinary, and QoL domains and total score of NIH-CPSI, IIEF-5, EHS, IPSS, and AUA QoL_US were employed in this study of patients with CP/CPPS who had been refractory to other prior treatments (n = 215; age range: 32–82 years; median age: 57.5 ± 12.4 years; modal age: 41 years). Results: For CP symptoms, the mean pre-ESWT NIH-CPSI total score of 27.1 ± 6.8 decreased by 31.3–53.6% over 12 months after ESWT. The mean pre-ESWT NIH-CPSI pain (12.5 ± 3.3), urinary (4.98 ± 2.7), and QoL (9.62 ± 2.1) domain scores improved by 2.3-fold, 2.2-fold, and 2.0-fold, respectively, by month 12 post-ESWT. Compared with the baseline IPSS of 13.9 ± 8.41, we recorded 27.1–50.9% amelioration of urinary symptoms during the 12 months post-ESWT. For erectile function, compared to pre-ESWT values, the IIEF-5 also improved by ~1.3-fold by month 12 after ESWT. This was corroborated by EHS of 3.11 ± 0.99, 3.37 ± 0.65, 3.42 ± 0.58, 3.75 ± 0.45, and 3.32 ± 0.85 at baseline, 1, 2, 6, and 12 months post-ESWT. Compared to the mean pre-ESWT QoL score (4.29 ± 1.54), the mean QoL values were 3.26 ± 1.93, 3.45 ± 2.34, 3.25 ± 1.69, and 2.6 ± 1.56 for months 1, 2, 6, and 12 after ESWT, respectively. Conclusions: This study shows ESWT, an outpatient and easy-to-perform, minimally invasive procedure, effectively alleviates pain, improves erectile function, and ameliorates quality of life in patients with refractory CP/CPPS.

101: Depression Mediates Poorer Quality of Life in Partners of Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

2006 ◽  
Vol 175 (4S) ◽  
pp. 33-33
Author(s):  
Dean A. Tripp ◽  
J. Curtis Nickel ◽  
Ashley K. Soryal ◽  
Kelly Smith ◽  
Caroline Pukall ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome
Sign in / Sign up

Export Citation Format

Share Document